Alendronate Dosing for 84-Year-Old Female
For an 84-year-old woman with osteoporosis, prescribe alendronate 70 mg once weekly (or 10 mg daily if weekly dosing is not tolerated), taken after an overnight fast with a full glass of water, remaining upright for at least 30 minutes before eating or taking other medications. 1, 2
Standard Dosing Regimen
The evidence strongly supports that alendronate 70 mg once weekly is therapeutically equivalent to 10 mg daily and is the preferred regimen for treatment of postmenopausal osteoporosis 1, 2. The weekly formulation offers:
- Equivalent efficacy in increasing bone mineral density
- Similar safety profile
- Better convenience and adherence
- Reduced frequency of dosing-related complications
Age-Specific Considerations
High-quality evidence demonstrates that bisphosphonates are at least as effective in older patients (including those over 75 years) as in younger patients 3. Your 84-year-old patient falls into the "very high fracture risk" category based on age alone, making her an excellent candidate for treatment 1.
For secondary prevention (which applies if she has osteoporosis, prior fractures, or T-score ≤-2.5), alendronate at this dose:
- Reduces clinical vertebral fractures by 55% (RR 0.45)
- Reduces hip fractures by 51% (RR 0.49)
- Reduces non-vertebral fractures by 20% (RR 0.80)
- Reduces wrist fractures by 46% (RR 0.54) 4
Critical Administration Instructions
Proper administration is essential to prevent esophageal complications:
- Take after overnight fast, first thing in morning
- Swallow with full glass (6-8 oz) of plain water only
- Remain upright (sitting or standing) for at least 30 minutes
- Wait 30 minutes before consuming food, beverages (other than water), or other medications
- Do not lie down for at least 30 minutes after taking 1, 2
Contraindications and Precautions to Assess
Before prescribing, verify the following:
Absolute Contraindications:
- Creatinine clearance <35 mL/min (calculate using Cockcroft-Gault formula with actual body weight, not estimated GFR) 1
- Hypocalcemia (must correct before starting)
- Inability to stand or sit upright for 30 minutes
- Esophageal abnormalities (achalasia, stricture, severe dysmotility) 1, 2
Important Safety Checks:
- Correct vitamin D deficiency and ensure adequate calcium intake (500-1000 mg daily) before starting 1
- Screen for active upper GI disease (use with caution in active esophageal disease)
- Assess dental health (though osteonecrosis of jaw is extremely rare with oral bisphosphonates) 2
Alternative Formulations
If your patient cannot tolerate the standard tablet:
- Liquid alendronate 70 mg weekly is equally effective and may be better tolerated in some patients 5
- Delayed-release risedronate (Atelvia) can be taken with food if upper GI issues are a concern, though it doesn't reduce GI adverse events 1
Duration of Therapy
Plan for 3-5 years of continuous treatment initially, then reassess fracture risk 1. In moderate-risk patients (T-score >-2.5 at femoral neck after treatment), consider a drug holiday of 1-3 years. However, given her advanced age (84 years), she likely remains at high fracture risk and may benefit from continued therapy beyond 5 years 1, 6.
When to Consider Injectable Alternatives
Consider switching to zoledronic acid 5 mg IV annually or denosumab 60 mg subcutaneously every 6 months if she:
- Cannot comply with strict oral administration requirements
- Has GI malabsorption (gastric bypass, celiac disease, Crohn's disease)
- Develops intolerable upper GI symptoms
- Has very high fracture risk (multiple vertebral fractures, very low T-scores) where anabolic agents might be preferred initially 1
Important caveat: If denosumab is ever used, she must transition to a bisphosphonate afterward to prevent rebound bone loss 1, 6.
Monitoring
- Bone mineral density: Reassess at 1-2 years to confirm treatment response
- Biochemical markers: Optional; bone turnover markers decrease within 3-6 months if treatment is effective 2, 7
- Calcium and vitamin D levels: Ensure adequacy throughout treatment
- Renal function: Monitor periodically, especially in elderly patients 1
Safety Profile in Elderly
The safety profile in your 84-year-old patient should be similar to younger postmenopausal women. Research specifically in elderly women (70-85 years) showed efficacy and tolerability were similar to younger women (60-69 years) 8. Common adverse events include mild, transient abdominal pain, dyspepsia, and acid regurgitation, but these occur at similar rates to placebo when taken correctly 2, 4.
Atypical femoral fractures are rare (1.78 per 100,000 with <2 years use; increases to >100 per 100,000 with ≥8 years use), but remain far less common than the fractures prevented by treatment 3, 6.